LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PF431396 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1485 | 3694 | 0.4022 | 0.0040 |
| SK-BR-3 | PF477736 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1409 | 3694 | 0.3815 | -0.0304 |
| SK-BR-3 | PF562271 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1783 | 3694 | 0.4829 | 0.1384 |
| SK-BR-3 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 4205 | 3694 | 1.1385 | 1.2307 |
| SK-BR-3 | PHA-793887 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1536 | 3694 | 0.4159 | 0.0269 |
| SK-BR-3 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1687 | 3694 | 0.4567 | 0.0948 |
| SK-BR-3 | PLX-4720 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3989 | 3694 | 1.0800 | 1.1333 |
| SK-BR-3 | QL-X-138 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1894 | 3694 | 0.5127 | 0.1882 |
| SK-BR-3 | QL-XII-47 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1164 | 3694 | 0.3153 | -0.1407 |
| SK-BR-3 | Radicicol | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1697 | 3694 | 0.4596 | 0.0996 |
| SK-BR-3 | Radicicol | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1577 | 3694 | 0.4269 | 0.0452 |
| SK-BR-3 | Seliciclib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3292 | 3694 | 0.8912 | 0.8187 |
| SK-BR-3 | Ruxolitinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3603 | 3694 | 0.9754 | 0.9591 |
| SK-BR-3 | XL147 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 4479 | 3694 | 1.2127 | 1.3543 |
| SK-BR-3 | Saracatinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3385 | 3694 | 0.9164 | 0.8608 |
| SK-BR-3 | Selumetinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3785 | 3694 | 1.0248 | 1.0413 |
| SK-BR-3 | Sirolimus | 1.11 | uM | LJP6 | 72 | hr | 1476 | 2197 | 3694 | 0.5949 | 0.3251 |
| SK-BR-3 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3608 | 3694 | 0.9769 | 0.9615 |
| SK-BR-3 | SU11274 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3901 | 3694 | 1.0560 | 1.0933 |
| SK-BR-3 | Fedratinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3042 | 3694 | 0.8236 | 0.7061 |
| SK-BR-3 | TGX221 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3584 | 3694 | 0.9702 | 0.9504 |
| SK-BR-3 | Torin1 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1335 | 3694 | 0.3615 | -0.0638 |
| SK-BR-3 | Torin2 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1307 | 3694 | 0.3540 | -0.0762 |
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 1303 | 3694 | 0.3528 | -0.0782 |
| SK-BR-3 | Trametinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2673 | 3694 | 0.7238 | 0.5398 |